IO Biotech, Inc. (IOBT)

NASDAQ: IOBT · IEX Real-Time Price · USD
1.680
-0.080 (-4.55%)
Mar 4, 2024, 4:30 PM EST - Market closed
-4.55%
Market Cap 115.95M
Revenue (ttm) n/a
Net Income (ttm) -79.97M
Shares Out 65.88M
EPS (ttm) -2.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 49,883
Open 1.800
Previous Close 1.760
Day's Range 1.590 - 1.800
52-Week Range 0.816 - 2.680
Beta 0.51
Analysts Strong Buy
Price Target 8.33 (+395.83%)
Earnings Date Mar 15, 2024

About IOBT

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 5, 2021
Employees 57
Stock Exchange NASDAQ
Ticker Symbol IOBT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for IOBT stock is "Strong Buy." The 12-month stock price forecast is $8.33, which is an increase of 395.83% from the latest price.

Price Target
$8.33
(395.83% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

IO Biotech to Present at 44th Annual Cowen Health Care Conference

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® pl...

7 days ago - GlobeNewsWire

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win® pl...

2 months ago - GlobeNewsWire

IO Biotech Announces 2023 Third Quarter Results

Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma Presente...

4 months ago - GlobeNewsWire

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology pla...

4 months ago - GlobeNewsWire

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Trial expected to reach the primary endpoint of progression free survival in the second half of 2025 Per-protocol interim analysis expected in mid-2024 NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- IO B...

4 months ago - GlobeNewsWire

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology pla...

4 months ago - GlobeNewsWire

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology pla...

4 months ago - GlobeNewsWire

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines, announced encouraging...

4 months ago - GlobeNewsWire

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology pla...

5 months ago - GlobeNewsWire

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology pl...

6 months ago - GlobeNewsWire

IO Biotech Announces 2023 Second Quarter Results

NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology pla...

7 months ago - GlobeNewsWire

IO Biotech Appoints Heidi Hunter to its Board of Directors

NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology pla...

7 months ago - GlobeNewsWire

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology pl...

7 months ago - GlobeNewsWire

IO Biotech, Inc. Announces $75 Million Private Placement Financing

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology pla...

7 months ago - GlobeNewsWire

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology pla...

7 months ago - GlobeNewsWire

IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer

NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology pl...

7 months ago - GlobeNewsWire

IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer

NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology pla...

8 months ago - GlobeNewsWire

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

NEW YORK, June 14, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology pla...

9 months ago - GlobeNewsWire

IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology pla...

9 months ago - GlobeNewsWire

IO Biotech to Present at the Jefferies Healthcare Conference

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology plat...

9 months ago - GlobeNewsWire

IO Biotech Announces 2023 First-Quarter Results

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology plat...

10 months ago - GlobeNewsWire

IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology pl...

1 year ago - GlobeNewsWire

IO Biotech to Participate in March 2023 Investor Conferences

NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® vaccine platf...

1 year ago - GlobeNewsWire

IO Biotech Announces Appointment of Devin Smith as General Counsel

Mr. Smith joins IO Biotech bringing over two decades of legal and compliance experience in the life science industries Mr. Smith joins IO Biotech bringing over two decades of legal and compliance expe...

1 year ago - GlobeNewsWire

IO Biotech Provides Business Update

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platfo...

1 year ago - GlobeNewsWire